

10/579791

IAP12 Rec'd PCT/PTO 18 MAY 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : New Application
Applicant : Sirpa JALKANEN
Filed : Herewith
TC/A.U. :
Examiner :

Docket No. : 3187-103
Customer No. : 06449
Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith
information that the Office may wish to consider in examination of the subject application.

Materials submitted for consideration are listed on the attached form PTO-1449.

Respectfully submitted,

By


Jeffrey L. Thnen

Attorney for Applicants
Registration No. 28,957
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known 10/579791	
				Application Number	New Application
				Filing Date	Herewith
				First Named Inventor	Sirpa JALKANEN
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	3187-103

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
		WO	03/007938	A1	AIDAN, INC.	01-30-2003	
		WO	02/102384	A1	ORTHOGENICS AS	12-27-2002	
		WO	03/006003	A1	BIOTIE THERAPIES CORP.	01-23-2003	
		WO	02/02090	A2	BIOTIE THERAPIES CORP.	01-10-2002	
		WO	02/38153	A1	BIOVITRUM AB	05-16-2002	
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known 10/579791	
				Application Number	New Application
				Filing Date	Herewith
				First Named Inventor	Sirpa JALKANEN
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	3187-103

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
		B.H. Ali, et al., "Gentamicin Nephrotoxicity in Rat: Some Biochemical Correlates", Pharmacology & Toxicology, 1992, Vol. 70, pp. 419-423		
		Jeffrey O'Sullivan, et al., "The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses", Biochimica et Biophysica Acta 1647, 2003, pp. 367-371		
Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.